BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37327699)

  • 1. Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.
    Xu H; Chen HC; Yang L; Yang G; Liang L; Yang Y; Tang H; Bao H; Wu X; Shao Y; An G; Wang Y
    ESMO Open; 2023 Jun; 8(3):101585. PubMed ID: 37327699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
    Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
    Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
    Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
    Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
    Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
    PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Zhang H; Liu M; Pan Z; Liu H; Chen J
    Front Immunol; 2021; 12():670040. PubMed ID: 34512623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.
    Shi Y; Shin DS
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
    Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
    Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
    Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
    Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
    Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
    Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
    Villatoro TM; Ma C; Pai RK
    Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.
    Chang G; Li W; Bai H; Duan J; Wang Z; Du X; Yu R; Wang Y; Wang M; Zhu Y; Zhang X; Li L; Wan R; Wang J
    Thorac Cancer; 2022 Nov; 13(21):2951-2959. PubMed ID: 36126963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes.
    Schwartz CJ; Pareja F; da Silva EM; Selenica P; Ross DS; Weigelt B; Brogi E; Reis-Filho JS; Wen HY
    Mod Pathol; 2021 Oct; 34(10):1850-1859. PubMed ID: 34079072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.